Brussels, 29/05/2013 (Agence Europe) - On 29 May, the European Parliament's environment and public health and food safety (ENVI) committee adopted the report by Glenis Wilmott (S&D, United Kingdom) on clinical trials by 64 votes for and one abstention. “We have managed to reach agreement on the main issues - especially transparency”, Wilmott stated. She also obtained a negotiating mandate to begin discussions immediately with the Council so as to accelerate the implementation of a new simplified framework - which is much awaited by all stakeholders. In her report, Wilmott welcomes the European Commission's proposal, which does not ignore patient safety but believes that certain points must be improved. Her report aims to strengthen transparency by requiring publication of a clinical study report via the EU portal and in the EU database. Wilmott also calls for fines to be issued if the sponsor does not conform to these requirements. Lastly, she proposes to clarify the role of ethics committees and to implement a voluntary contributions platform in order to strengthen their cooperation and sharing of best practice. Nearly 800 amendments were tabled by MEPs on Wilmott's report. (IL/transl.fl)